Sequoia Financial Advisors LLC Purchases Shares of 3,342 Revolution Medicines, Inc. $RVMD

Sequoia Financial Advisors LLC purchased a new stake in Revolution Medicines, Inc. (NASDAQ:RVMD) during the second quarter, according to its most recent 13F filing with the SEC. The firm purchased 3,342 shares of the company’s stock, valued at approximately $626,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. Equitable Holdings Inc. purchased a new stake in shares of Revolution Medicines during the 2nd quarter valued at $963,000. State of Wyoming acquired a new position in Revolution Medicines during the 2nd quarter valued at about $1,769,000. Handelsbanken Fonder AB raised its stake in Revolution Medicines by 243.6% in the second quarter. Handelsbanken Fonder AB now owns 212,275 shares of the company’s stock valued at $39,755,000 after buying an additional 150,500 shares during the last quarter. Bank of New York Mellon Corp acquired a new stake in Revolution Medicines in the second quarter worth about $112,566,000. Finally, Assenagon Asset Management S.A. purchased a new stake in shares of Revolution Medicines during the second quarter worth about $37,547,000. Hedge funds and other institutional investors own 94.34% of the company’s stock.

Analyst Ratings Changes

RVMD has been the subject of several research analyst reports. TD Cowen raised shares of Revolution Medicines to a “strong-buy” rating in a research report on Monday, August 24th. Weiss Ratings reissued a “sell (d-)” rating on shares of Revolution Medicines in a research report on Friday, July 17th. Royal Bank Of Canada upped their price target on shares of Revolution Medicines from $203.00 to $251.00 and gave the company an “outperform” rating in a research note on Thursday, August 27th. Stifel Nicolaus raised their price target on shares of Revolution Medicines from $215.00 to $230.00 and gave the stock a “buy” rating in a report on Wednesday, September 9th. Finally, Morgan Stanley started coverage on shares of Revolution Medicines in a research note on Thursday, September 10th. They set an “overweight” rating and a $255.00 price objective for the company. Two research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $226.17.

Revolution Medicines News Roundup

Here are the key news stories impacting Revolution Medicines this week:

• Positive Sentiment: Revolution Medicines recently received regulatory approval for a new medicine, validating its approach to treating certain cancers. The treatment could potentially become the most-prescribed therapy in its indication, improving the company’s long-term commercial outlook. Revolution Medicines Just Hit a Major Milestone. Is the Stock a Buy?
• Neutral Sentiment: A comparison article weighing Axsome Therapeutics against Revolution Medicines highlights RVMD as a healthcare investment candidate, but does not provide a clearly new company-specific catalyst. Axsome Therapeutics vs. Revolution Medicines: Which Healthcare Stock Is a Better Buy in 2026?
• Negative Sentiment: Five company insiders, including the CFO and COO, collectively sold approximately $5.8 million of RVMD shares at $199.24 apiece. The filings state that the transactions were made to cover tax withholding obligations tied to vested equity awards, rather than for discretionary reasons. Nevertheless, the cluster of sales can create short-term supply and sentiment pressure. The insiders continued to hold substantial positions after the transactions. Revolution Medicines insider transaction filing

Revolution Medicines Trading Down 3.0%

Revolution Medicines stock opened at $190.95 on Friday. The company has a quick ratio of 11.38, a current ratio of 11.38 and a debt-to-equity ratio of 0.40. Revolution Medicines, Inc. has a 52 week low of $42.18 and a 52 week high of $224.31. The company has a market capitalization of $40.93 billion, a price-to-earnings ratio of -21.65 and a beta of 1.40. The stock has a 50-day moving average price of $199.57 and a 200 day moving average price of $159.57.

Revolution Medicines (NASDAQ:RVMD) last issued its quarterly earnings results on Wednesday, August 5th. The company reported ($3.06) earnings per share for the quarter, missing the consensus estimate of ($2.04) by ($1.02). During the same period in the prior year, the business posted ($1.31) EPS. Sell-side analysts anticipate that Revolution Medicines, Inc. will post -8.87 EPS for the current year.

Insiders Place Their Bets

In other news, COO Margaret Horn sold 4,967 shares of the stock in a transaction on Wednesday, September 16th. The shares were sold at an average price of $199.24, for a total value of $989,625.08. Following the sale, the chief operating officer owned 149,680 shares in the company, valued at $29,822,243.20. This represents a 3.21% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Stephen Kelsey sold 5,569 shares of the firm’s stock in a transaction on Wednesday, September 16th. The stock was sold at an average price of $199.24, for a total transaction of $1,109,567.56. Following the transaction, the insider directly owned 286,307 shares of the company’s stock, valued at approximately $57,043,806.68. This trade represents a 1.91% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last three months, insiders sold 300,119 shares of company stock worth $60,605,043. Company insiders own 7.60% of the company’s stock.

Revolution Medicines Profile

Revolution Medicines, Inc is a clinical-stage biotechnology company focused on developing targeted treatments for cancer. The company specializes in therapies designed to inhibit oncogenic RAS signaling, a pathway involved in many difficult-to-treat cancers, including tumors driven by KRAS mutations.

Its pipeline includes investigational RAS(ON) inhibitors intended to target active forms of RAS proteins. Key programs have included daraxonrasib (RMC-6236), an oral inhibitor being studied in cancers with a range of RAS mutations, as well as mutation-selective programs such as RMC-9805 for KRAS G12D and RMC-6291 for KRAS G12C.